[An experimental study of the antisecretory and antiulcer activities of kviditen].
Quiditene-(qunuclidyl-3)-di-(thyenel-2)carbinole hydrochloride was studied by using various experimental models. The agent was compared with H2-blockers. When gastrically used, quiditene in doses of 5-50 mg/kg dose-dependently decreased gastric acid secretion and prevented acute gastric mucosal lesions. As cimetidine and ranitidine, the agent accelerated chronic gastric ulcer healing. Quiditene has been allowed for clinical studies in Russia.
Kaminka
M E
ME
Tupikina
S M
SM
Mashkovskiĭ
M D
MD
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002908:Chronic Disease; D002927:Cimetidine / Q000494:pharmacology / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D011812:Quinuclidines / Q000494:pharmacology* / Q000627:therapeutic use; D011899:Ranitidine / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology; D013312:Stress, Physiological / Q000150:complications; D013997:Time Factors
D000897:Anti-Ulcer Agents; D011812:Quinuclidines; C093777:quiditene; D002927:Cimetidine; D011899:Ranitidine
Eksperimental'noe issledovanie antisekretornoĭ i protivoiazvennoĭ aktivnosti kviditena.